Chuan-Tao Zuo
Overview
Explore the profile of Chuan-Tao Zuo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wen S, Ju Z, Wang Y, Zuo C, Sun X, Zheng T
ACS Appl Mater Interfaces
. 2025 Feb;
17(9):13461-13470.
PMID: 39973147
Accumulating evidence supports an important role of phospholipase D3 (PLD3) in the pathogenesis of Alzheimer's disease (AD), while the actual expression level and distribution of PLD3 remains controversial in AD....
2.
Liu F, Lu J, Li X, Ge J, Sun Y, Yen T, et al.
Eur J Nucl Med Mol Imaging
. 2024 Oct;
52(2):586-598.
PMID: 39352424
Purpose: The identification of tau accumulation within living brains holds significant potential in facilitating accurate diagnosis of progressive supranuclear palsy (PSP). While visual assessment is frequently employed, standardized methods for...
3.
Chen K, Wang M, Wu J, Zuo C, Huang Y, Wang W, et al.
Alzheimers Dement
. 2024 Feb;
20(4):2516-2525.
PMID: 38329281
Introduction: The objective of this study is to investigate the incremental value of amyloid positron emission tomography (Aβ-PET) in a tertiary memory clinic setting in China. Methods: A total of...
4.
Li J, Song J, Suckling J, Wang Y, Zuo C, Zhang C, et al.
Neurobiol Aging
. 2023 Dec;
134:106-114.
PMID: 38056216
Based on the 'AT(N)' system, individuals with normal amyloid biomarkers but abnormal tauopathy or neurodegeneration biomarkers are classified as non-Alzheimer's disease (AD) pathologic change. This study aimed to assess the...
5.
Hou X, Suckling J, Shen X, Liu Y, Zuo C, Huang Y, et al.
J Transl Med
. 2023 Oct;
21(1):768.
PMID: 37904154
Background: Early prevention of Alzheimer's disease (AD) is a feasible way to delay AD onset and progression. Information on AD prediction at the individual patient level will be useful in...
6.
Sun Y, Gan L, Peng F, Zhou X, Chen Q, Liu F, et al.
Parkinsonism Relat Disord
. 2023 May;
111:105441.
PMID: 37201327
Introduction: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of autosomal dominantly inherited Parkinson's disease (PD). Recently, a novel pathogenic variant (N1437D; c.4309A > G;...
7.
Li J, Song J, Suckling J, Wang Y, Zuo C, Zhang C, et al.
Res Sq
. 2023 Apr;
PMID: 37034751
Background: According to the new 'AT(N)' system, those with a normal amyloid biomarker but with abnormal tauopathy or biomarkers of neurodegeneration or neuronal injury, have been labeled suspected non-Alzheimer's pathophysiology...
8.
Liu F, Lu J, Sun Y, Li L, Yang Y, Zhao J, et al.
Phenomics
. 2023 Mar;
3(1):22-33.
PMID: 36939793
Supplementary Information: The online version contains supplementary material available at 10.1007/s43657-022-00077-8.
9.
Shen X, Huang S, Cui M, Zhao Q, Guo Y, Huang Y, et al.
Clin Chem
. 2023 Mar;
69(4):411-421.
PMID: 36861369
Background: Plasma glial fibrillary acidic protein (GFAP) has emerged as a promising biomarker in neurological disorders, but further evidence is required in relation to its usefulness for diagnosis and prediction...
10.
Huang S, Chen S, Cui M, Zhao M, Shen X, Guo Y, et al.
Mov Disord
. 2023 Feb;
38(4):676-682.
PMID: 36781585
Background: Development of disease-modifying therapeutic trials of progressive supranuclear palsy (PSP) urges the need for sensitive fluid biomarkers. Objectives: The objectives of this study were to explore the utility of...